Companies › Wuhan Createrna Science and Technology
1 active drug program in 3 registered trials: 2 Phase 3, 1 Phase 2; Hematology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| MY008211A tablets Complement pathway inhibitor | – | Phase 3 | Paroxysmal Nocturnal Hemoglobinuria; Paroxysmal Nocturnal Haemoglobinuria (PNH); Paroxysmal Nocturnal Hemoglobinuria (PNH) | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06932471 | MY008211A tablets | Phase 3 | Paroxysmal Nocturnal Hemoglobinuria | Hematology | Dec 2025 |
| NCT06932744 | MY008211A tablets | Phase 3 | Paroxysmal Nocturnal Haemoglobinuria (PNH) | Hematology | Dec 2025 |
| NCT06933914 | MY008211A tablets | Phase 2 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | Hematology | Dec 2026 |
No annotated target.
–
Bioverativ, a Sanofi company Hangzhou Gensciences Biopharmaceutical Gritgen Therapeutics Forma Therapeutics Pharmanutra
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.